This project takes the team’s recently developed minimally-invasive “liquid biopsy” and extends it to address clinical needs, focusing on two liver diseases: Nonalcoholic fatty liver disease (NAFLD) and acute post-transplantation liver rejection. The researchers will recruit patient cohorts and perform detailed molecular analysis of repeated samples of plasma and liver biopsies. They will analyze them using advanced AI methods to determine how information from patients can impact the diagnosis and treatment in these patients.